TFRC and lung carcinoma: To overcome the constraints of unloaded drugs and enhance treatment outcomes, Zhu et al. created novel T7 peptide-based nanoparticles (T7-CMCS-BAPE, CBT) premised on carboxymethyl chitosan (CMCS), which were also likely to bind to the transferrin receptor (TfR) presented on lung carcinoma cells and accurately control the drug release depending on the pH and reactive oxygen species (ROS) levels.